Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
8.14
-0.06 (-0.73%)
Jul 29, 2026, 12:20 PM EDT - Market open
Adicet Bio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 36.25 | 38.92 | 56.5 | 159.71 | 257.66 | 277.54 |
Short-Term Investments | 101.35 | 119.61 | 119.81 | - | - | - |
Cash & Short-Term Investments | 137.59 | 158.53 | 176.3 | 159.71 | 257.66 | 277.54 |
Cash Growth | -8.54% | -10.08% | 10.39% | -38.01% | -7.17% | 193.34% |
Accounts Receivable | - | - | - | - | - | 0.19 |
Other Current Assets | 2.48 | 2.4 | 3.83 | 2.56 | 3.38 | 4.71 |
Total Current Assets | 140.07 | 160.93 | 180.14 | 162.27 | 261.04 | 282.44 |
Net Property, Plant & Equipment | 26.36 | 28.48 | 36.75 | 44.2 | 48.98 | 35 |
Goodwill | - | - | - | - | 19.46 | 19.46 |
Other Long-Term Assets | 2.95 | 2.95 | 3.33 | 0.82 | 1.21 | 2.04 |
Total Assets | 169.38 | 192.36 | 220.22 | 207.3 | 330.69 | 338.94 |
Accounts Payable | 2.93 | 4.74 | 4.83 | 2.63 | 4.4 | 3.26 |
Accrued Expenses | 12.49 | 13.61 | 11.43 | 13.44 | 12.81 | 6.68 |
Current Portion of Leases | 2.88 | 3.19 | 3.13 | 3.22 | 2.49 | 1.57 |
Unearned Revenue | - | - | - | - | - | 4.81 |
Total Current Liabilities | 18.3 | 21.53 | 19.39 | 19.29 | 19.71 | 16.32 |
Long-Term Leases | 11.02 | 11.55 | 14.1 | 17.7 | 18.53 | 19.38 |
Other Long-Term Liabilities | - | 0.06 | 0.12 | 0.13 | 0.11 | 0.12 |
Total Long-Term Liabilities | 11.02 | 11.61 | 14.22 | 17.83 | 18.65 | 19.49 |
Total Liabilities | 29.32 | 33.15 | 33.61 | 37.12 | 38.35 | 35.81 |
Common Stock | 0 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 775.04 | 773.8 | 684.48 | 550.94 | 530.45 | 471.45 |
Accumulated Other Comprehensive Income | -0.04 | 0.1 | 0.02 | - | - | - |
Retained Earnings | -634.94 | -614.7 | -497.89 | -380.77 | -238.11 | -168.32 |
Shareholders' Equity | 140.07 | 159.21 | 186.61 | 170.18 | 292.34 | 303.13 |
Total Liabilities & Equity | 169.38 | 192.36 | 220.22 | 207.3 | 330.69 | 338.94 |
Total Debt | 13.9 | 14.74 | 17.23 | 20.92 | 21.02 | 20.94 |
Net Cash (Debt) | 123.69 | 143.79 | 159.07 | 138.79 | 236.63 | 256.6 |
Net Cash Growth | -7.82% | -9.60% | 14.61% | -41.35% | -7.78% | 251.63% |
Net Cash Per Share | 15.22 | 20.87 | 28.97 | 51.59 | 92.16 | 132.64 |
Book Value | 140.07 | 159.21 | 186.61 | 170.18 | 292.34 | 303.13 |
Book Value Per Share | 17.24 | 23.10 | 33.98 | 63.26 | 113.86 | 156.70 |
Tangible Book Value | 140.07 | 159.21 | 186.61 | 170.18 | 272.88 | 283.67 |
Tangible Book Value Per Share | 17.24 | 23.10 | 33.98 | 63.26 | 106.28 | 146.63 |